跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,883 条关于
“Vida Ventures”
全部
3,883
临床试验
2,757
药物
65
机构
42
资讯
1,019
4个月前
UCB Acquires Candid Therapeutics for $2.2 Billion, Advancing T-Cell Engager Platform for Autoimmune Diseases
5个月前
Adcendo Secures $75 Million Series C to Advance First-in-Class ADC Pipeline for High Unmet Need Cancers
2年前
Third Arc Secures $165M Series A to Advance Novel T-Cell Engager Platform for Cancer and Inflammation
3个月前
InduPro Doses First Patient in Phase 1 Trial of Proximity-Based Bispecific ADC IDP-001, Closes $77M Series B
3个月前
Swiss Biotech Startups Take Center Stage at Boston Roadshow as US Investors Signal Selective Recovery in 2026
8个月前
Volastra Therapeutics Expands KIF18A Inhibitor Program Following Positive Clinical Data
9个月前
Protego Biopharma Raises $130M to Advance Novel Protein Stabilization Approach for AL Amyloidosis
2年前
Volastra Therapeutics Initiates Phase Ib Trial of Sovilnesib for Platinum-Resistant Ovarian Cancer
去年
Antares Therapeutics Launches with $177 Million Series A to Advance First-in-Class Cancer Precision Medicines
去年
Volastra's Novel KIF18A Inhibitor Shows Promising Results in Ovarian Cancer Patients
第 1 页,共 102 页
上一页
下一页